awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q41337231-49220B6F-162C-47C5-B239-A8DA305992AA
Q41337231-49220B6F-162C-47C5-B239-A8DA305992AA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41337231-49220B6F-162C-47C5-B239-A8DA305992AA
The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.
P2860
Q41337231-49220B6F-162C-47C5-B239-A8DA305992AA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q41337231-49220B6F-162C-47C5-B239-A8DA305992AA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4f6da3df170aec7ea2e2a65f0c944c259a9faa83
P2860
Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?